NCT02783300 - An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

297

Participants

Timeline

Start Date

August 30, 2016

Primary Completion Date

August 30, 2023

Study Completion Date

August 30, 2023

Conditions

Neoplasms

Interventions

DRUG

GSK3326595

GSK3326595 will be administered with and without food, in tablet and capsule formulation.

DRUG

Pembrolizumab

Pembrolizumab will be administered.

Trial Locations (15)

10065

GSK Investigational Site, New York

33076

GSK Investigational Site, Bordeaux

33136

GSK Investigational Site, Miami

37203

GSK Investigational Site, Nashville

69373

GSK Investigational Site, Lyon

75230

GSK Investigational Site, Dallas

78229

GSK Investigational Site, San Antonio

80218

GSK Investigational Site, Denver

94805

GSK Investigational Site, Villejuif

T6G 1Z2

GSK Investigational Site, Edmonton

K1H 8L6

GSK Investigational Site, Ottawa

M5G 1Z5

GSK Investigational Site, Toronto

1066 CX

GSK Investigational Site, Amsterdam

2333 ZA

GSK Investigational Site, Leiden

3015 GD

GSK Investigational Site, Rotterdam